CVS HEALTH Corp (CVS) Factsheet
CVS HEALTH Corp (CVS) Stock Analysis
Analysis from 10-Q filed 2025-10-29. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 3.7%. FCF margin 1.8%. D/E 0.8x. Source: 10-Q filed 2025-10-29.
| Metric | Value | Context |
|---|---|---|
| ROIC | 3.7% | Below expectations |
| FCF Margin | 1.8% | Cash flow pressure |
| Debt/Equity | 0.8x | Moderate leverage |
ROIC 3.7% — Bottom 50% of sector peers. FCF margin 1.8% — Bottom 50%.
Explore CVS HEALTH Corp: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for CVS: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: CVS HEALTH Corp earns 3.7% ROIC, Bottom 50% in Consumer Discretionary
ROIC TTM 3.7%, sector median 8.0%, Bottom 50%. DuPont: NOPAT margin 1.2% × asset turnover 1.6x. Gross margin 44.7%. Operating margin 1.5%. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 3.7% | Red flag | Below sector median of 8.0% |
| Return on Equity (ROE) | 3.9% | Warning | Moderate equity returns |
| Gross Margin | 44.7% | Good | Strong pricing power |
| Operating Margin | 1.5% | Warning | Moderate operational efficiency |
Cash Flow: CVS HEALTH Corp generates $7.4B FCF at 1.8% margin, positive NaN/8 quarters
FCF TTM $7.4B. FCF margin 1.8%, Bottom 50%. OCF/Net income 3.5x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 1.8% | Warning | Thin cash margins |
| Free Cash Flow (TTM) | $7.4B | Good | Positive cash generation |
| OCF/Net Income | 3.5x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: CVS HEALTH Corp at 0.8x leverage
Debt/Equity 0.8x. Total debt $60.5B, cash & investments $12.0B. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.8x | Adequate | Moderate leverage |
| Net Cash Position | $-48.5B | Warning | Net debt position |
Valuation: CVS HEALTH Corp trades at 30.4x earnings
P/E 30.4x. EV/Sales 0.3x. FCF yield 8.3%. Dividend yield 3.8%. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| P/E Ratio | 30.4x | Adequate | Premium valuation |
| EV/Sales | 0.3x | Excellent | Attractive revenue multiple |
| FCF Yield | 8.3% | Excellent | Attractive cash return |
| Dividend Yield | 3.8% | Adequate | Meaningful income |
Capital Allocation: CVS HEALTH Corp returns 3.8% shareholder yield
Total shareholder yield 3.8% (div 3.8%). Capital returned $3.4B TTM. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.8% | Good | Dividend + buyback yield combined |
| Total Capital Returned (TTM) | $3.4B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 3.7% | Bottom 50% | 0.5x below |
| Free Cash Flow Margin | 1.8% | Bottom 50% | 0.8x below |
| Gross Margin | 44.7% | Top 50% | 1.1x above |
| Operating Margin | 1.5% | Bottom 50% | 0.3x below |
| Return on Equity (ROE) | 3.9% | Bottom 50% | 0.4x below |
| P/E Ratio | 30.4x | N/A | - |
Financial Scorecard
| Metric | CVS | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 3.7% | Red flag | Bottom 50% of sector (median: 8.0%) |
| Free Cash Flow Margin | 1.8% | Warning | Bottom 50% of sector (median: 2.2%) |
| Gross Margin | 44.7% | Good | Top 50% of sector (median: 39.0%) |
| Debt to Equity Ratio | 78.1% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 30.4x | Adequate | Growth premium |
| Free Cash Flow Yield | 8.3% | Excellent | High cash return |
Frequently Asked Questions
Q: What is CVS HEALTH Corp's Return on Invested Capital (ROIC)?
CVS HEALTH Corp (CVS) has a trailing twelve-month Return on Invested Capital (ROIC) of 3.7%. Sector median 8.0%. Source: 10-Q filed 2025-10-29.
Q: What is CVS HEALTH Corp's Free Cash Flow Margin?
CVS HEALTH Corp (CVS) has a free cash flow margin of 1.8%, generating $7.4 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-29.
Q: What is CVS HEALTH Corp's P/E ratio and how does it compare to peers?
CVS HEALTH Corp (CVS) trades at a P/E ratio of 30.4x, which is above the sector median of N/A. EV/Sales 0.3x. FCF yield 8.3%. Source: 10-Q filed 2025-10-29.
Q: Does CVS HEALTH Corp pay a dividend?
CVS HEALTH Corp (CVS) currently pays a dividend yield of 3.8%. Total shareholder yield (dividend + buybacks) 3.8%. Source: 10-Q filed 2025-10-29.
Q: How much debt does CVS HEALTH Corp have?
CVS HEALTH Corp (CVS) has a debt-to-equity ratio of 0.8x with total debt of $60.5 billion. Net debt $48.5 billion. Source: 10-Q filed 2025-10-29.
Q: What is CVS HEALTH Corp's revenue and earnings growth?
CVS HEALTH Corp (CVS) grew revenue by 7.6% year-over-year. EPS -45.1% YoY. Source: 10-Q filed 2025-10-29.
Q: How does CVS HEALTH Corp compare to competitors in Consumer Discretionary?
Compared to other companies in Consumer Discretionary, CVS HEALTH Corp (CVS) shows: ROIC 3.7%, sector median 8.0% (Bottom 50%). FCF margin 1.8%, sector median 2.2% (Bottom 50%). Gross margin 44.7%, 5.7pp above sector median. These rankings are based on MetricDuck's analysis of all Consumer Discretionary companies with available SEC filings.
Q: What warning signs should I watch for with CVS HEALTH Corp?
Quantitative warning flags for CVS HEALTH Corp (CVS): 1) FCF margin 1.8% (below 5%). Source: 10-Q filed 2025-10-29.
Data Source: Data sourced from 10-Q filed 2025-10-29. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.